China Medical System (HKG:0867) signed a license, collaboration, and distribution agreement with Alpha Cognition for its Zunveyl drug for mild to moderate dementia from Alzheimer's disease, according to a Wednesday filing with the Hong Kong Exchange.

Under the agreement, CMS will have exclusive rights to develop, register, manufacture, import, export, and commercialize the drug in Asia ex-Japan, Australia, and New Zealand, the filing said.

AlphaCognition will still manufacture and supply the drug in Australia and New Zealand, the filing said.